Related references
Note: Only part of the references are listed.Designer vaccine nanodiscs for personalized cancer immunotherapy
Rui Kuai et al.
NATURE MATERIALS (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy
Chao Wang et al.
NATURE BIOMEDICAL ENGINEERING (2017)
Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook
Chao Wang et al.
ADVANCED MATERIALS (2017)
Extracellular vesicles for drug delivery
Pieter Vader et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
The Basis of Oncoimmunology
A. Karolina Palucka et al.
CELL (2016)
Biomaterials for enhancing anti-cancer immunity
Sandeep T. Koshy et al.
CURRENT OPINION IN BIOTECHNOLOGY (2016)
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Lena M. Kranz et al.
NATURE (2016)
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations
Axel Hoos
NATURE REVIEWS DRUG DISCOVERY (2016)
β-cell-mimetic designer cells provide closed-loop glycemic control
Mingqi Xie et al.
SCIENCE (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
A Facile Approach to Functionalize Cell Membrane-Coated Nanoparticles
Hao Zhou et al.
THERANOSTICS (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Biomaterials and emerging anticancer therapeutics: engineering the microenvironment
Luo Gu et al.
NATURE REVIEWS CANCER (2016)
Engineered T cells: the promise and challenges of cancer immunotherapy
Andrew D. Fesnak et al.
NATURE REVIEWS CANCER (2016)
Anticancer Platelet-Mimicking Nanovehicles
Quanyin Hu et al.
ADVANCED MATERIALS (2015)
Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy
Michael S. Goldberg
CELL (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Cell membrane-camouflaged nanoparticles for drug delivery
Brian T. Luk et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Nanoparticle biointerfacing by platelet membrane cloaking
Che-Ming J. Hu et al.
NATURE (2015)
In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity
Geoffrey M. Lynn et al.
NATURE BIOTECHNOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Engineering opportunities in cancer immunotherapy
Laura Jeanbart et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Virus-mimetic nanovesicles as a versatile antigen-delivery system
Pengfei Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Cell or Cell Membrane-Based Drug Delivery Systems
Songwei Tan et al.
THERANOSTICS (2015)
Biopolymer implants enhance the efficacy of adoptive T-cell therapy
Sirkka B. Stephan et al.
NATURE BIOTECHNOLOGY (2015)
Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy
Jaeyun Kim et al.
NATURE BIOTECHNOLOGY (2015)
Extracellular vesicles as drug delivery systems: Lessons from the liposome field
Roy van der Meel et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery
Ronnie H. Fang et al.
NANO LETTERS (2014)
Structure-based programming of lymph-node targeting in molecular vaccines
Haipeng Liu et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
A carbon nanotube-polymer composite for T-cell therapy
Tarek R. Fadel et al.
NATURE NANOTECHNOLOGY (2014)
The production and regulation of IgE by the immune system
Lawren C. Wu et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Bioinspired Exosome-Mimetic Nanovesicles for Targeted Delivery of Chemotherapeutics to Malignant Tumors
Su Chul Jang et al.
ACS NANO (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Re: Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients with Renal Cell Carcinoma Editorial Comment
Samir S. Taneja
JOURNAL OF UROLOGY (2012)
Re: Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer Editorial Comment
Samir S. Taneja
JOURNAL OF UROLOGY (2012)
Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy
Jason Park et al.
NATURE MATERIALS (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform
Che-Ming J. Hu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Therapeutic cell engineering with surface-conjugated synthetic nanoparticles
Matthias T. Stephan et al.
NATURE MEDICINE (2010)
Molecular signature of CD8+ T cell exhaustion during chronic viral infection
E. John Wherry et al.
IMMUNITY (2007)
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
David H. Munn et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase
G Frumento et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Share Paper
